Persistent ctDNA Correlates With Disease Recurrence in HR+/HER2– Early Breast Cancer
December 6th 2023
Detection of circulating tumor DNA with the Signatera assay was associated with disease recurrence in patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer at 24 months post-randomization to treatment with adjuvant abemaciclib and endocrine therapy.